JP2024535867A5 - - Google Patents
Info
- Publication number
- JP2024535867A5 JP2024535867A5 JP2024517040A JP2024517040A JP2024535867A5 JP 2024535867 A5 JP2024535867 A5 JP 2024535867A5 JP 2024517040 A JP2024517040 A JP 2024517040A JP 2024517040 A JP2024517040 A JP 2024517040A JP 2024535867 A5 JP2024535867 A5 JP 2024535867A5
- Authority
- JP
- Japan
- Prior art keywords
- amino
- ethyl
- alkyl
- cancer
- pyrimidine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163244775P | 2021-09-16 | 2021-09-16 | |
| US63/244,775 | 2021-09-16 | ||
| PCT/US2022/042431 WO2023043630A1 (en) | 2021-09-16 | 2022-09-02 | Compounds having n-arylpyrimidin-2-amine derivatives as therapeutic agents |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024535867A JP2024535867A (ja) | 2024-10-02 |
| JP2024535867A5 true JP2024535867A5 (enExample) | 2025-06-23 |
Family
ID=85603404
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024517040A Pending JP2024535867A (ja) | 2021-09-16 | 2022-09-02 | 治療薬としてn-アリールピリミジン-2-アミン誘導体を有する化合物 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20240270699A1 (enExample) |
| EP (1) | EP4401735A4 (enExample) |
| JP (1) | JP2024535867A (enExample) |
| WO (1) | WO2023043630A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3242316A1 (en) | 2021-12-30 | 2023-07-06 | Biomea Fusion, Inc. | Pyrazine compounds as inhibitors of flt3 |
| WO2023138612A1 (en) * | 2022-01-19 | 2023-07-27 | Silexon Ai Technology Co., Ltd. | Heterocyclic compounds useful as hpk1 inhibitors |
| IL325314A (en) * | 2023-06-15 | 2026-02-01 | Lynk Pharmaceuticals Co Ltd | Tyk2 inhibitors, compositions and methods thereof |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1518855B1 (en) * | 2002-06-28 | 2011-10-26 | Astellas Pharma Inc. | Diaminopyrimidinecarboxa mide derivative |
| US7528143B2 (en) * | 2005-11-01 | 2009-05-05 | Targegen, Inc. | Bi-aryl meta-pyrimidine inhibitors of kinases |
| JP5705720B2 (ja) * | 2008-04-16 | 2015-04-22 | ポートラ ファーマシューティカルズ, インコーポレイテッド | Sykまたはjakキナーゼ阻害剤としての2,6−ジアミノ−ピリミジン−5−イル−カルボキサミド |
| ES2635504T3 (es) * | 2009-01-21 | 2017-10-04 | Rigel Pharmaceuticals, Inc. | Derivados de N2-(3-piridilo o fenil)-N4-(4-piperidil)-2,4-pirimidinadiamina útiles en el tratamiento de enfermedades inflamatorias, toimmunitarias o proliferativas |
| US8367689B2 (en) * | 2009-05-06 | 2013-02-05 | Portola Pharmaceuticals, Inc. | Inhibitors of JAK |
| CN111032630B (zh) * | 2017-08-18 | 2022-12-16 | 北京韩美药品有限公司 | 一种化合物,其药物组合物及其用途及应用 |
| WO2019090198A1 (en) * | 2017-11-06 | 2019-05-09 | Bristol-Myers Squibb Company | Isofuranone compounds useful as hpk1 inhibitors |
| WO2022098809A1 (en) * | 2020-11-09 | 2022-05-12 | Merck Sharp & Dohme Corp. | Diaminopyrimidine carboxamide inhibitors of hpk1 |
| CN121851009A (zh) * | 2021-01-22 | 2026-04-14 | 苏州信诺维医药科技股份有限公司 | Hpk1抑制剂、其制备方法、药物组合物及其应用 |
-
2022
- 2022-09-02 JP JP2024517040A patent/JP2024535867A/ja active Pending
- 2022-09-02 WO PCT/US2022/042431 patent/WO2023043630A1/en not_active Ceased
- 2022-09-02 EP EP22870513.3A patent/EP4401735A4/en active Pending
-
2024
- 2024-03-13 US US18/604,472 patent/US20240270699A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI770113B (zh) | 2-雜芳基-3-氧代-2,3-二氫噠嗪-4-甲醯胺 | |
| RU2310651C2 (ru) | Азотсодержащие ароматические производные, фармацевтическая композиция, их содержащая, способ лечения и применение | |
| JP2022520448A5 (enExample) | ||
| CN109863140B (zh) | 3-氧代-2,6-二苯基-2,3-二氢哒嗪-4-甲酰胺 | |
| CN103097375B (zh) | Ccr2的环己基-氮杂环丁烷拮抗剂 | |
| CN114206848A (zh) | 作为整合应激通路的调节剂的被取代的环烷基化合物 | |
| TW201927756A (zh) | 整合應激路徑之調節劑 | |
| CN1639153A (zh) | 吲哚基马来酰亚胺衍生物 | |
| JP4324791B2 (ja) | 2−アシルアミノチアゾール誘導体又はその塩 | |
| JP2014139226A5 (enExample) | ||
| JP2017531679A (ja) | キナーゼ阻害剤として有用なインドールカルボキシアミド | |
| RU2017145650A (ru) | Ингибиторы тирозинкиназы брутона | |
| JP2023541522A (ja) | 低分子量タンパク質分解物質及びその適用 | |
| JP2015531773A (ja) | スルファモイル−アリールアミド及びb型肝炎の治療のための薬剤としてのその使用 | |
| JP2016515096A (ja) | スルファモイル−アリールアミドおよびb型肝炎を処置するための医薬品としてのその使用 | |
| KR20170066650A (ko) | Egfr 돌연변이 키나아제 활성을 조절하기 위한 화합물 및 조성물 | |
| JP2017505762A5 (enExample) | ||
| CN102725283A (zh) | 作为蛋白激酶抑制剂的化合物和组合物 | |
| CN107108554B (zh) | 作为midh1抑制剂用于治疗肿瘤的1-环己基-2-苯基氨基苯并咪唑 | |
| EP3324954A1 (en) | Aminonapthoquinone compounds and pharmaceutical composition for blocking ubiquitination-proteasome system in diseases | |
| WO2019034153A1 (zh) | 一种化合物,其药物组合物及其用途及应用 | |
| JP6184866B2 (ja) | 新規抗がん剤 | |
| AU2015233559A1 (en) | Inhibitors of the Wnt signalling pathways | |
| JP2024539633A5 (enExample) | ||
| JP2024508817A (ja) | B型肝炎ウイルス感染症の処置および予防のためのベンゾチアゾリルビシクロ[1.1.1]ペンタン誘導体 |